Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20174363 | 0.94 | PDK2 (0.34) | MAPK1KMT2AALOX5PDK2MEN1 | |
| SCHEMBL20174357 | 0.93 | ENPP3 (0.33) | MAPK1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL20174391 | 0.88 | CYP1A1 (0.37) | MAPK1KMT2APDK2ALDH1A1MAPT | |
| SCHEMBL20174355 | 0.88 | KMT2A (0.33) | MAPK1KMT2APDK2MEN1ALDH1A1 | |
| SCHEMBL20174347 | 0.87 | MAPK1 (0.33) | MAPK1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20174322 | 0.87 | PDK2 (0.39) | MAPK1KMT2APDK2MEN1 | |
| SCHEMBL20174361 | 0.87 | PDK2 (0.39) | MAPK1KMT2APDK2MEN1 | |
| SCHEMBL20174398 | 0.87 | PDK2 (0.39) | MAPK1KMT2APDK2MEN1 | |
| SCHEMBL20174327 | 0.87 | PDK2 (0.34) | MAPK1KMT2AALOX5PDK2MEN1 | |
| SCHEMBL20174359 | 0.86 | KMT2A (0.34) | MAPK1KMT2APDK2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2020-08-11 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738034-B2 | Spiro compound and organic light-emitting device comprising same | CRY1, NR2E3, ERG | MAPK1 3742/4885KMT2A 1480/4885ALOX5 2705/4885 |
| US-20180141933-A1 | SPIRO COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, NR2E3, ERG | MAPK1 3742/4885KMT2A 1480/4885ALOX5 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.